BRPI1011354A2 - 6- (6-O-cycloalkyl or 6-nh-cycloalkyl-triazolo pyridazine sulfanyl) benzothiazoles and benzimadazole derivatives: preparation, use as medicaments and use as metal inhibitors - Google Patents

6- (6-O-cycloalkyl or 6-nh-cycloalkyl-triazolo pyridazine sulfanyl) benzothiazoles and benzimadazole derivatives: preparation, use as medicaments and use as metal inhibitors

Info

Publication number
BRPI1011354A2
BRPI1011354A2 BRPI1011354A BRPI1011354A BRPI1011354A2 BR PI1011354 A2 BRPI1011354 A2 BR PI1011354A2 BR PI1011354 A BRPI1011354 A BR PI1011354A BR PI1011354 A BRPI1011354 A BR PI1011354A BR PI1011354 A2 BRPI1011354 A2 BR PI1011354A2
Authority
BR
Brazil
Prior art keywords
cycloalkyl
benzimadazole
benzothiazoles
sulfanyl
medicaments
Prior art date
Application number
BRPI1011354A
Other languages
Portuguese (pt)
Inventor
Ugolini Antonio
Ronan Baptiste
Nemecek Conception
Damour Dominique
Bacque Eric
Wentzler Sylvie
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BRPI1011354A2 publication Critical patent/BRPI1011354A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
BRPI1011354A 2009-02-06 2010-02-04 6- (6-O-cycloalkyl or 6-nh-cycloalkyl-triazolo pyridazine sulfanyl) benzothiazoles and benzimadazole derivatives: preparation, use as medicaments and use as metal inhibitors BRPI1011354A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0900510A FR2941949B1 (en) 2009-02-06 2009-02-06 DERIVATIVES OF 6- (6-O-CYCLOALKYL OR 6-NH-CYCLOALKYL-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS INHIBITORS OF MET.
PCT/FR2010/050177 WO2010089506A1 (en) 2009-02-06 2010-02-04 Derivatives of 6-(6-o-cycloalkyl or 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors

Publications (1)

Publication Number Publication Date
BRPI1011354A2 true BRPI1011354A2 (en) 2019-09-24

Family

ID=40863635

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011354A BRPI1011354A2 (en) 2009-02-06 2010-02-04 6- (6-O-cycloalkyl or 6-nh-cycloalkyl-triazolo pyridazine sulfanyl) benzothiazoles and benzimadazole derivatives: preparation, use as medicaments and use as metal inhibitors

Country Status (18)

Country Link
EP (1) EP2393790A1 (en)
JP (1) JP2012517407A (en)
KR (1) KR20110126660A (en)
CN (1) CN102388029A (en)
AR (1) AR075248A1 (en)
AU (1) AU2010212231A1 (en)
BR (1) BRPI1011354A2 (en)
CA (1) CA2751525A1 (en)
CO (1) CO6400222A2 (en)
EA (1) EA201171010A1 (en)
FR (1) FR2941949B1 (en)
IL (1) IL214407A0 (en)
MA (1) MA33102B1 (en)
MX (1) MX2011008312A (en)
SG (1) SG173558A1 (en)
TW (1) TW201040187A (en)
UY (1) UY32419A (en)
WO (1) WO2010089506A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5957526B2 (en) 2011-09-15 2016-07-27 ノバルティス アーゲー 6-Substituted 3- (quinolin-6-ylthio)-[1,2,4] triazolo [4,3-A] pyrazine as tyrosine kinase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
WO2007064797A2 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
ZA200804681B (en) * 2005-11-30 2009-11-25 Vertex Pharma Inc Inhibitors of C-Met and uses thereof
US8030305B2 (en) * 2005-12-21 2011-10-04 Janssen Pharmaceutica N.V. Triazolopyridazines as kinase modulators
JP2009538899A (en) * 2006-05-30 2009-11-12 ファイザー・プロダクツ・インク Triazolopyridazine derivatives
PE20121506A1 (en) * 2006-07-14 2012-11-26 Amgen Inc TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS
AU2007309149C1 (en) * 2006-10-23 2013-04-04 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
PA8792501A1 (en) * 2007-08-09 2009-04-23 Sanofi Aventis NEW DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICATIONS, PHARMACEUTICAL COMPOSITIONS AND NEW MAIN USE AS MET INHIBITORS.

Also Published As

Publication number Publication date
KR20110126660A (en) 2011-11-23
EA201171010A1 (en) 2012-03-30
MX2011008312A (en) 2011-11-02
MA33102B1 (en) 2012-03-01
EP2393790A1 (en) 2011-12-14
AU2010212231A1 (en) 2011-08-25
FR2941949B1 (en) 2011-04-01
JP2012517407A (en) 2012-08-02
WO2010089506A1 (en) 2010-08-12
IL214407A0 (en) 2011-09-27
SG173558A1 (en) 2011-09-29
FR2941949A1 (en) 2010-08-13
AR075248A1 (en) 2011-03-16
UY32419A (en) 2010-09-30
CA2751525A1 (en) 2010-08-12
CO6400222A2 (en) 2012-03-15
TW201040187A (en) 2010-11-16
CN102388029A (en) 2012-03-21

Similar Documents

Publication Publication Date Title
HK1253532A1 (en) Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
IL220129A (en) Benzamide derivatives, compositions comprising same and use thereof for the treatment of cancer
HK1153926A1 (en) Purin derivatives for use in the treatment of fab-related diseases fab-
PL2768937T3 (en) Formulations, their use as or for the manufacture of dishwashing agents and their manufacture
ZA201101105B (en) Purine derivatives for use in the treatment of allergic,inflammatory and infectious diseases
IL216967B (en) 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives and use thereof for the treatment of diseases
AP2012006292A0 (en) Topical use of hydroxytyrosol and derivatives for the prevention of HIV infection.
PL2841549T3 (en) Formulations, use of same as or for manufacture of dish-washing agents and their manufacture
PL2841548T3 (en) Formulations, use of same as or for manufacture of dish-washing agents and their manufacture
BRPI1008019A2 (en) 6- (6-substituted-triazolo pyridazine-sulfanyl) 5-fluorobenzothiazoles and 5-fluorobenzimidazole derivatives: preparation, use as medicines and use as metal inhibitors
BR112013014915A2 (en) curative composition and treatment methods
HK1207385A1 (en) Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies
BRPI1008188A2 (en) "6- (6-nh-substituted-triazolopyridazine sulfanyl) benzothiazoles and benzimidazole derivatives: preparation, use as medicines and use as inhibitors of met"
IT1400386B1 (en) KIT OF PARTS FOR THE TREATMENT AND / OR PREVENTION OF SKIN ULCERS
BRPI1008232A2 (en) 6- (6-O-substituted-triazolo pyridazine sulfanyl) benzothiazoles and benzimidazole derivatives: preparation, use as medicaments and use as metal inhibitors
ZA201107883B (en) Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containint these derivatives
ZA201104945B (en) Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds
PL2616062T3 (en) Use of derivatives of pentaphyrine as antimicrobial and desinfectant agents
BRPI1011354A2 (en) 6- (6-O-cycloalkyl or 6-nh-cycloalkyl-triazolo pyridazine sulfanyl) benzothiazoles and benzimadazole derivatives: preparation, use as medicaments and use as metal inhibitors
EP2630925A4 (en) Treatment tool for medical use, and manipulator
HK1172568A1 (en) Soluble pharmaceutical forms of n,n-diaminodiphenyl sulphone for optimum use in the treatment of various diseases nn-
ZA201304035B (en) Diarylpyridazinone derivatives,preparation thereof,and use thereof for the treatment of humans
PT2456445E (en) Agent for the treatment of skin conditions
FR2966151B1 (en) 6- (ALKYL- OR CYCLOALKYL-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS MET INHIBITORS
TH0901005786A (en) Purine derivatives for use in the treatment of allergies, inflammation and infectious diseases.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.